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Arthrocentesis was performed and sterile synovial fluid was found. Magnetic reso-
nance images displayed a bone fragment detachment from the humeral condyle
of the right elbow with synovium thickening and persistent effusion: the diagnosis
of OCD was pointed out.
The patient showed minor dysmorphisms (i.e. dolicocephaly, hypotelorism,
arched palate and brachydactyly of the IV finger of both hands) and parents
reported a previous episode of OCD when he was 12: at that time, symptoms
resolved with non-weightbearing and non-steroidal anti-inflammatory therapy
after few days. Furthermore, the patient went under regular endocrinologist fol-
low-up for short stature since he was 8. At the age of 10, his height was 123 cm,
SDS 2.4, and growth hormone (GH) stimulation tests showed partial response to
insulin tolerance test (GH peak 6.27 ng/mL). Bone age at the X-Ray of right hand
and wrist was delayed of 12 months. Human recombinant GH replacement ther-
apy was administered without significant growth-velocity improvement. Although
the patient came to observation because of suspected elbow septic arthritis, we
re-considered the diagnosis: namely, i. recurrent episodes of OCD; ii. short stature
that was poorly responsive to the human recombinant GH treatment, iii. mild skel-
etal and facial dysmorphisms, led us to hypothesize a form of aggrecanopathy.
Molecular analysis of the ACAN gene revealed the novel missense variant
c.6970T>C, p.Trp2324Arg in the G3 domain of the protein. Notably, another muta-
tion of the G3 domain (c.7249G>A) has been previously related to aggrecanop-
athy2. Intra-familial molecular analysis allowed us to detect the same gene variant
in other three subjects (the mother and 2 siblings) affected only by brachydactily
and short stature.
Conclusion: A patient carrying a novel mutation of the ACAN gene presented an
atypical form of aggrecanopathy mimicking inflammatory and/or septic arthritis
associated with slight short stature and bone dysmorphisms. Further studies are
needed to investigate a possible role of this novel ACAN gene variant in the
inflammatory articular involvement.
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Background: Syndecan-4 plays a critical role in cartilage degradation during
osteoarthritis (OA).
Objectives: To investigate the expression and localization of syndecan-4 in dif-
ferent OA joint tissues.
Methods: Syndecan-4 mRNA levels were quantified by RT-PCR in human OA
primary cells to compare non-hypertrophic vs hypertrophic articular chondrocytes,
non-sclerotic vs sclerotic subchondral osteoblasts and normal/reactive vs
inflamed fibroblasts-like synoviocytes. Syndecan-4 was localized by immunohis-
tochemistry in knee, hip or shoulder OA bone/cartilage biopsies. Syndecan-4 was
quantified by immmunoassay in chondrocytes culture supernatant and cell
fraction.
Results: By immunohistochemistry, syndecan-4 was observed in chondrocytes
clusters in the superficial zone of OA knee, but not in OA hip or shoulder cartilage.
No staining was observed in the deep zone of cartilage and in subchondral bone.
No difference between syndecan-4 expression level in sclerotic and non-sclerotic
osteoblasts was observed. Syndecan-4 tended to be increased in inflamed syno-
viocytes compared to normal/reactive ones but difference was not significant. Dif-
ferentiated hypertrophic chondrocytes from knee, but not from hip cartilage,
expressed more syndecan-4 than non-hypertrophic cells. Using an immunoassay
for the extracellular domain of syndecan-4, we found 68% of the syndecan-4 in
the culture supernatant of OA chondrocytes culture, suggesting that a large major-
ity of the syndecan-4 is shed and released in the extracellular medium. The shed-
ding rate was not affected by hypertrophic differentiation state of the chondrocytes
or their joint origin.
Conclusion: Syndecan-4 could be related to the hypertrophic differentiation of
the OA chondrocytes, but the pathway seems to be knee specific. Even if chon-
drocytes clusters are seen in OA knee, hip and shoulder cartilage and hypertro-
phic differentiation appears in knee and hip OA articular chondrocytes, syndecan-
4 synthesis only increased in knee. These findings suggests the presence of bio-
chemical difference between articular cartilage according to their location and that
syndecan-4 could be a biochemical marker specific for knee OA.
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Background: Coll2-1 is a nine amino acid sequence (HRGYPGLDG) specific of
type II collagen which is released during cartilage degradation. This peptide is
located in the triple helicoidal part of type II collagen molecule(1,2,3).
Objectives: This study aims to assess intra-individual biological variability of
serum cartilage specific biomarker Coll2-1 and define the best standardized con-
ditions for blood sampling in clinical trials.
Methods: Blood samples were taken from 122 subjects with diagnosed knee
osteoarthritis (KOA) at a single timepoint as well as from 15 healthy subjects
under various conditions, including fasting condition (before or after breakfast and
lunch), sampling time (at 8am, 9am, 12pm, 2pm and 5pm), sampling season (at
baseline and after 2, 16, 52 and 68 weeks), physical activity (after a resting week-
end versus working day), blood treatment (blood clotting from 1h to 24h at room
temperature or 4°C; centrifugation at room temperature or 4°C) and type of blood
collection tube (dry tube versus dry tube with gel separator). Type II collagen-spe-
cific biomarker Coll2-1 was measured using ELISA (Artialis Groups SA, Liège,
Belgium) on all collected samples.
Results: There was no significant difference on Coll2-1 values between samples
collected at any of the five sampling times (p=0.85) or at any of the sampling days
measured (p=0.58). None of the sampling parameters tested had a significant
impact on Coll2-1 value (clotting time, clotting temperature and temperature of
blood centrifugation (p=0.93), type of tube: p=0.38) when all data from healthy
subjects were pooled (n=631 samples). On the contrary,subjects with knee OA
had a significantly higher Coll2-1 concentration then healthy subjects (OA: 481+/-
144nM vs Healthy 192+/-32nM, p<0,001).
Conclusion: Coll2-1 assay is sufficiently robust for use during OA clinical trials.
Coll2-1 measurement is not affected by subject specific conditions such as fast-
ing, resting state, circadian rhythm, seasonality, nor by sampling process factors
such as type of dry tube, clotting patterns and centrifugation temperature.
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